" "
Satellite Banner
Informatics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

PathoQuest Raises EUR 3.8 Million in Series B Financing Round

Published: Friday, July 12, 2013
Last Updated: Friday, July 12, 2013
Bookmark and Share
The new round of financing will be used for the first clinical study of a disruptive Next Generation Sequencing cloud-based diagnostic assay for infectious diseases.

PathoQuest has announced the closing of a new fundraising of EUR 3.8 million. This round brings in two new investors, Idinvest and Aurinvest, in addition to the existing investor Kurma Life Science Partners.

PathoQuest develops solutions for high unmet needs in clinical diagnosis of infectious diseases. The company, founded in 2010, previously raised EUR 2 million in March 2011.

The additional funds will allow PathoQuest to launch the first clinical study of a novel NGS-SaaS (Software as a Service) cloud based diagnostic assay. This assay is a bioinformatics workflow that is designed to assist the diagnostic decision-making.

This clinical study will target diagnosis of severe multi-etiological-based infectious episodes in immuno-compromised patients.

This immuno-suppression can be congenital or acquired, whether through immuno-suppressing treatment post-transplant or through anticancer chemotherapy.

For immuno-compromised patients, the current leading diagnostic approaches remain unsatisfactory. Current approaches are biased, because, as the targets are defined, in principle users can only find what they are looking for.

With NGS, users can identify any target, without prior selection. PathoQuest’s assay will allow identification of pathogens in two days, compared with several weeks with current approaches.

As a result, the diagnostic is more accurate and the cost is reduced. PathoQuest intends to launch a first commercial product in 2015, following an extension of this clinical trial in the US in the coming months.

“We are delighted to launch the first clinical trial with an unbiased diagnostic approach in the field of infectious diseases,” said Prof. Marc Eloit, president and CSO and Luc Boblet, CEO of PathoQuest.

Using a unique combination of proprietary sample prep and bio-IT algorithms, PathoQuest’s business model is based on ‘Software as a Service’ (SaaS).

In the area of infectious diseases, PathoQuest is the only company on the market to combine NGS of the whole genome of a pathogen with SaaS, while offering cloud computing access.

PathoQuest will act as an alternative to well established solutions on the market by offering reagent kits and distributed bio-IT services through this cloud computing model.

“We think the results of the first PathoQuest clinical trial will position the company to meet high medical needs with a good value solution,” said Thierry Laugel, managing partner at Kurma Life Sciences. “Helping to create highly innovative companies from an academic background continues to build the knowledge and experience of Kurma.”

“We are pleased to invest in such a promising project and to work in close connection with both the Pasteur Institute and KLS partners,” said Michel Demont, president of Aurinvest. “PathoQuest, is our sixth investment in the life sciences sector and our second with the Pasteur Institute.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
‘Precision Prevention’ for Colorectal Cancer
New risk prediction model — not yet ready for clinical use — incorporates genetic, lifestyle and environmental risk factors.
Characterizing Cancerous Genomic Variations
Tested on large tumor genomics database, REVEALER method allows researchers to connect genomics to cell function.
Uncovering Hidden Genomic Alterations that Drive Cancers
Tested on large tumor genomics database, REVEALER method allows researchers to connect genomics to cell function.
Spotting DNA Repair Genes Gone Awry
Ludwig researchers develop a two-pronged approach for identifying genes responsible for fixing DNA damage that can trigger cancer when compromised.
Interpreting “Dark Matter” DNA
Scientists at the Gladstone Institutes have invented a new way to read and interpret the human genome.
A Programming Language for Living Cells
New language lets researchers design novel biological circuits.
The Epigenetics of Childhood Cancer
Qlucore software enables researchers to more easily study the genetic influences behind childhood cancer.
Mining Whole Exome Data to Improve Cancer Therapies
New tool interprets the raw data of whole exome tumor sequencing and then matches the cancer’s unique genetics to FDA-approved targeted treatments.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!